Stryker reports 9.0% organic sales growth and 17.9% adjusted EPS growth in Q2 2026

Filed July 30, 2026 · Period ending July 30, 2026 · ~1 min read

Key Changes

• high

  Q2 2026 net sales reached $6.6 billion with 9.0% organic growth driven by volume gains across both MedSurg/Neurotechnology (9.2%) and Orthopaedics (8.6%) segments.

  Exhibit 99.1 view on EDGAR →
• high

  Adjusted EPS grew 17.9% to $3.69 as adjusted operating margin expanded 170 basis points to 27.4%, reflecting operational leverage and recovery from the cyber incident.

  Exhibit 99.1 view on EDGAR →
• high

  Management narrowed full-year 2026 guidance to 8.3%–9.3% organic sales growth and $14.95–$15.10 adjusted EPS, citing recovery momentum from the March 2026 cyber incident.

  Exhibit 99.1 view on EDGAR →